

**CARELLA, BYRNE, BAIN, GILFILLAN
CECCHI, STEWART & OLSTEIN**
6 Becker Farm Road
Roseland, New Jersey 07068
(973) 994-1700
(973) 994-1744 (FAX)

OPERATOR: JaniceS

TIME COMPLETED: _____

EXT. NO.: 524DATE: October 2, 2002OUR FILE NO.: 176650-96

NAME

Diana Dudash

FIRM:

PTO

FAX NO.

703-746-5058FROM: William SquireTotal Pages Including Transmittal Sheet: 10

COMMENTS:

As requested, I am faxing our Amendment mailed on May 24, 2002,
(filed June 3, 2002) in response to the Office Action dated Feb. 25,
2002.

IF YOU HAVE ANY PROBLEMS WITH THIS TRANSMISSION, OR DO NOT RECEIVE
THE NUMBER OF PAGES NOTED, PLEASE CONTACT THE FAX OPERATOR AT (973)
994-1700 (EXT. 211)

CONFIDENTIALITY NOTE: The documents accompanying this telecopy transmission
contain information from the law firm of Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart &
Olstein, which is confidential and/or legally privileged. The information contained in this
facsimile is intended only for the use of the individual named above and others who have been
specifically authorized to receive it. If the one receiving it is not the intended recipient, you are
hereby notified that any dissemination, distribution or copy of this communication is strictly
prohibited. If you have received this telecopy in error, please notify us by telephone immediately
so that we can arrange for the return of the original documents to us at once. Thank you.

The original of this document will be sent by:

☐
☐

Ordinary Mail
Messenger

☐
☐

Overnight Mail
This will be the only form of
delivery of this Document

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Suggy S. Chrai
SERIAL NO. : 09/774,346
FILED : January 31, 2001
FOR : Pharmaceutical Product
and Method of Making
EXAMINER : Michael A. Williamson
ART UNIT: : 1616
ATTORNEY DOCKET: 176650-96

5/C
2/3/03

AMENDMENT UNDER 37 CFR 1.111

Box Non-fee Amendment
Commissioner for Patents
Washington, DC 20231

Sir:

This paper is in response to the Office Action dated February 25, 2002 having a response due date set to expire on May 28, 2002.

IN THE CLAIMS

Cancel claims 36-37.

Amend the claims as follows:

1 (Twice amended). A product comprising:

a substrate; and

a plurality of discrete pharmaceutical or diagnostic unit dosage forms associated with the substrate, each unit dosage form including at least one active ingredient, said at least one active ingredient being deposited in separate discrete spaced locations on the substrate, each location comprising the active ingredient present in each of the unit